← All trials
NCT05950906
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2023
- Primary completion
- Mar 26, 2024
- Completion date
- Apr 30, 2024
- First posted
- Jul 18, 2023
- Last posted
- Jul 19, 2023
- Enrollment
- 88
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- California Institute for Biomedical ResearchLead sponsor
- Michael J. Fox Foundation for Parkinson's ResearchCollaborator
- Alzheimer’s Drug Discovery FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.